The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Adenosine Deaminase-Severe Combined Immunodeficiency Market Between 2026 And 2030?
The market for adenosine deaminase-severe combined immunodeficiency has shown substantial growth in recent years. Its valuation is anticipated to rise from $5.94 billion in 2025 to $6.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.6%. Historically, the market’s expansion occurred amidst conditions such as limited awareness of ADA-SCID, a scarcity of gene therapy solutions, a dependency on supportive care treatments, an absence of specialized treatment centers, and a high occurrence of treatment delays.
The adenosine deaminase-severe combined immunodeficiency market size is expected to show significant growth in the upcoming period. It is projected to climb to $8.11 billion in 2030, reflecting a compound annual growth rate (CAGR) of 6.4%. This anticipated expansion over the forecast duration can be attributed to progress in autologous stem cell therapies, enhanced availability of enzyme replacement therapy, an increase in specialized hospitals and clinics, higher pediatric diagnosis rates, and rising healthcare funding allocated to rare genetic disorders. Important trends observed during this forecast period encompass the wider acceptance of enzyme replacement therapies, an increase in the development and accessibility of gene therapy solutions, a rise in stem cell transplantation procedures, the broadening of pediatric treatment programs for ADA-SCID, and an intensified focus on comprehensive supportive care and patient monitoring.
Access Your Free Sample Report For In-Depth Market Analysis:
What Leading Drivers Are Supporting The Adenosine Deaminase-Severe Combined Immunodeficiency Market Expansion?
The adenosine deaminase-severe combined immunodeficiency market is anticipated to experience growth driven by the increasing prevalence of genetic disorders. Genetic disorders are defined as medical conditions resulting from either inherited or spontaneous abnormalities or mutations within an individual’s DNA. Several factors contribute to this rising prevalence, including advancements in diagnostic technologies, enhanced public awareness, increasing parental age, environmental influences, and overall population expansion. This growing incidence of genetic disorders, particularly conditions like adenosine deaminase-severe combined immunodeficiency (ADA-SCID), consequently boosts the demand for sophisticated diagnostic methods and specific therapeutic interventions. As an example, the Cystic Fibrosis Trust, a UK-based national charity, reported in October 2024 that the number of individuals living with cystic fibrosis (CF) in the UK increased from 11,148 in 2022 to 11,318 in 2023. Thus, the increasing occurrence of genetic disorders is a primary driver for the adenosine deaminase-severe combined immunodeficiency market’s expansion.
Which Segment Categories Are Included In The Adenosine Deaminase-Severe Combined Immunodeficiency Market Segment Analysis?
The adenosine deaminase-severe combined immunodeficiency market covered in this report is segmented –
1) By Treatment Type: Enzyme Replacement Therapy (ERT), Gene Therapy, Stem Cell Transplantation, Supportive Care Treatments
2) By Route of Administration: Intravenous, Subcutaneous
3) By End-User: Hospitals, Specialty Clinics
Subsegments:
1) By Enzyme Replacement Therapy (ERT): Pegylated Adenosine Deaminase, Non-Pegylated Adenosine Deaminase
2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy, Viral Vector-Mediated Gene Therapy
3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant, Umbilical Cord Blood Transplant
4) By Supportive Care Treatments: Antimicrobial Therapy, Immune System Support
What Emerging Trends Are Seen In The Adenosine Deaminase-Severe Combined Immunodeficiency Market?
Major organizations operating in the adenosine deaminase-severe combined immunodeficiency treatment market are concentrating on developing sophisticated solutions, including in-house gene therapy production, to improve patient access, lower treatment costs, and ensure continuous supply. In-house gene therapy production signifies the strategy of manufacturing autologous hematopoietic stem cells, which are genetically modified with a healthy ADA gene, within the organization’s own facility, thereby decreasing reliance on commercial manufacturers. For instance, in February 2025, the Fondazione Telethon, an Italy-based nonprofit biomedical research organization, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etuvetidigene autotemcel, a gene therapy initially created for ADA-SCID and now also targeting Wiskott-Aldrich Syndrome. This therapy involves a single administration of autologous CD34+ stem and progenitor cells transduced with a lentiviral vector encoding the functional gene, showing promising safety and efficacy results in treated patients.
Who Are The Active Companies Shaping The Adenosine Deaminase-Severe Combined Immunodeficiency Market?
Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are GlaxoSmithKline plc, Chiesi Farmaceutici S.p.A., Orchard Therapeutics PLC, Rocket Pharmaceuticals, Novartis AG, Bluebird Bio, Spark Therapeutics, Leadiant Biosciences, Sigma-Tau Pharmaceuticals, Astellas Pharma, Takeda Pharmaceutical Company, Pfizer Inc, Sanofi, Bristol-Myers Squibb, Roche Holding AG, Johnson & Johnson, AbbVie Inc, Gilead Sciences, CSL Limited, Bayer AG
Get The Full Adenosine Deaminase-Severe Combined Immunodeficiency Market Report:
Which Region Leads The Adenosine Deaminase-Severe Combined Immunodeficiency Market In Terms Of Market Share?
North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2025. The regions covered in the adenosine deaminase-severe combined immunodeficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Adenosine Deaminase-Severe Combined Immunodeficiency Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Adenosine Deaminase-Severe Combined Immunodeficiency Market 2026, By The Business Research Company
Acne Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report
Adeno Associated Viral Vectors Market Report 2026
Immunoassay Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model